. . . . . . . . . "0"^^ . "NT14300" . . "Aetiology, pathogenesis and clinical course of skin and immunopathological adverse events of biological therapy in inflammatory bowel disease"@en . "Crohn\u00B4s disease; ulcerative colitis; biological therapy; tumour necrosis factor alpha; immunopathology; adverse event"@en . " ulcerative colitis" . "2015-12-31+01:00"^^ . . . "1"^^ . " immunopathology" . "Biological therapy of CD and UC is associated with occurrence of adverse events of unknown aetiology in a proportion of patients. From 10 to 20% of patients experience various skin complications, while others suffer from other immunopathological complications, mainly arthral and muscular. We have previously identified decreased activity of deoxyribonuclease I (DNase I) enzyme as a risk factor of skin complications. The current project will be focused on systematic research of epidemiology, etiopathogenesis, clinical course and risk factors of skin and other immunopathological adverse events of biological therapy and based on collaboration of clinical researchers and specialists in the field of immunology, histopathology and laboratory diagnostics including methods of molecular biology. The results of the project can have a direct implication in clinical practice providing a better safety of biological therapy in IBD."@en . " tumour necrosis factor alpha" . "0"^^ . . "Etiologie, patogeneze a klinick\u00FD pr\u016Fb\u011Bh ko\u017En\u00EDch a imunopatologick\u00FDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F biologick\u00E9 l\u00E9\u010Dby idiopatick\u00FDch st\u0159evn\u00EDch z\u00E1n\u011Bt\u016F" . . "0"^^ . " biological therapy" . "2015-01-22+01:00"^^ . "0"^^ . "2013-05-01+02:00"^^ . "Crohn\u00B4s disease" . "Biologick\u00E1 l\u00E9\u010Dba Crohnovy choroby a ulcer\u00F3zn\u00ED kolitidy je u \u010D\u00E1sti nemocn\u00FDch spojena s v\u00FDskytem ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F, jejich\u017E etiologie nebyla dosud objasn\u011Bna. U 10-20% nemocn\u00FDch se objevuj\u00ED ko\u017En\u00ED zm\u011Bny a dosud p\u0159esn\u011B neur\u010Den\u00E1 \u010D\u00E1st pacient\u016F trp\u00ED dal\u0161\u00EDmi imunopatologick\u00FDmi komplikacemi, zejm\u00E9na kloubn\u00EDmi a svalov\u00FDmi. Ji\u017E d\u0159\u00EDve jsme identifikovali jako rizikov\u00FD faktor ko\u017En\u00EDch komplikac\u00ED sn\u00ED\u017Eenou aktivitu deoxyribonukle\u00E1zy I. Na rozs\u00E1hl\u00E9m souboru nemocn\u00FDch budeme prov\u00E1d\u011Bt systematick\u00FD v\u00FDzkum epidemiologie, etiopatogeneze, klinick\u00E9ho obrazu a rizikov\u00FDch faktor\u016F ko\u017En\u00EDch a imunopatologicky indukovan\u00FDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F biologick\u00E9 terapie. P\u0159edpokl\u00E1d\u00E1me spolupr\u00E1ci klinick\u00FDch v\u00FDzkumn\u00EDk\u016F a specialist\u016F v oblasti imunologie, histopatologie a laboratorn\u00ED diagnostiky, v\u010Detn\u011B metod molekul\u00E1rn\u00ED biologie. V\u00FDsledky v\u00FDzkumu mohou m\u00EDt bezprost\u0159edn\u00ED p\u0159\u00EDnos pro bezpe\u010Dnost biologick\u00E9 l\u00E9\u010Dby st\u0159evn\u00EDch z\u00E1n\u011Bt\u016F." . . "http://www.isvav.cz/projectDetail.do?rowId=NT14300"^^ . "2014-03-21+01:00"^^ . . .